Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa

International Journal of Antimicrobial Agents

Volumn 26, Issue 5, 2005, Pages 366-372

  Roveta, Simona ^a   Schito, Anna Maria ^a   Marchese, Anna ^a   Schito, Gian Carlo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cystic fibrosis; Mutant prevention concentration; Susceptibility tests; Time kill

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; DRUG UTILIZATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; CYSTIC FIBROSIS; DIOXOLANES; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; OPPORTUNISTIC INFECTIONS; PIPERAZINES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLINES; QUINOLONES;

EID: 26944440482     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.07.015     Document Type: Article

References (36)

1. R.T. Sadikot, T.S. Blackwell, J.W. Christman, and A.S. Prince Pathogen-host interactions in Pseudomonas aeruginosa pneumonia Am J Respir Crit Care Med 171 2005 1209 1223
2. G.B. Pier, and R. Ramphal Pseudomonas aeruginosa G.L. Mandell J.E. Bennett R. Dolin Mandell, Douglas, and Bennett's principles and practice of infectious diseases 6th ed. 2005 Elsevier Philadelphia, PA 2587 2615
3. R.L. Gibson, J.L. Burns, and B.W. Ramsey Pathophysiology and management of pulmonary infections in cystic fibrosis Am J Respir Crit Care Med 168 2003 918 951
4. M. Paul, and L. Leibovici Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia Lancet Infect Dis 5 2005 192 193
5. G. Manno, M. Cruciani, and L. Romano Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre Int J Antimicrob Agents 25 2005 193 197
6. G. Blandino, A. Marchese, and F. Ardito Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital-acquired infections Int J Antimicrob Agents 24 2004 515 518
7. I. Friedland, G. Gallagher, T. King, and G.L. Woods Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States J Chemother 16 2004 437 441
8. J.A. Karlowsky, M.E. Jones, C. Thornsberry, A.T. Evangelista, Y.C. Yee, and D.F. Sahm Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies Clin Infect Dis 40 Suppl. 2 2005 S89 S98
9. S.J. Keam, and C.M. Perry Prulifloxacin Drugs 64 2004 2221 2234
10. T. Yoshida, and S. Mitsuhashi Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone Antimicrob Agents Chemother 37 1993 793 800
11. G. Prats, C. Roig, E. Miro, F. Navarro, and B. Mirelis In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones Eur J Clin Microbiol Infect Dis 21 2002 328 334
12. M.P. Montanari, M. Mingoia, and P.E. Varaldo In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates Antimicrob Agents Chemother 45 2001 3616 3622
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 15th International Supplement. CLSI document M100-S15. Wayne, PA: CLSI; 2005.
14. M.P. Montanari, L. Ferrante, E. Tili, I. Cochetti, V. Rossi, and P.E. Varaldo Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin J Chemother 17 2005 138 142
15. National Committee for Clinical Laboratory Standards Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T 1992 NCCLS Villanova, PA
16. G.A. Pankuch, M.R. Jacobs, and P.C. Appelbaum Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology Antimicrob Agents Chemother 38 1994 2065 2072
17. M.A. Dawis, H.D. Isenberg, K.A. France, and S.G. Jenkins In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms J Antimicrob Chemother 51 2003 1203 1211
18. J.M. Blondeau, X. Zhao, G. Hansen, and K. Drlica Mutant prevention concentration of fluoroquinolones for clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 433 488
19. Hansen G, Blondeau JM. Selection and characterization of fluoroquinolone resistant Pseudomonas aeruginosa by ciprofloxacin (Cpx) and levofloxacin (Lfx) using high density cultures. In: 13th ECCMID; Glasgow, UK; 2003 May 10-13 [Abstract].
20. W.E. Shams, and M.E. Evans Guide to selection of fluoroquinolones in patients with lower respiratory tract infections Drugs 65 2005 949 991
21. L.L. Marcusson, S.K. Olofsson, P.K. Lindgren, O. Cars, and D. Hughes Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli J Antimicrob Chemother 55 2005 938 943
22. J.M. Blondeau, G. Hansen, K. Metzler, and P. Hedlin The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration J Chemother 16 Suppl. 3 2004 1 19
23. K. Drlica The mutant selection window and antimicrobial resistance J Antimicrob Chemother 52 2003 11 17
24. K.G. Naber, B. Bergman, and M.C. Bishop EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU) Eur Urol 40 2001 576 588
25. J.W. Warren, E. Abrutyn, and J.R. Hebel Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA) Clin Infect Dis 29 1999 745 758
26. F.M. Wagenlehner, W. Weidner, and K.G. Naber Emerging drugs for bacterial urinary tract infections Expert Opin Emerg Drugs 10 2005 275 298
27. G. Carmignani, A.F. De Rose, L. Olivieri, E. Salvatori, M.T. Rosignoli, and P. Dionisio Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections Urol Int 74 2005 326 331
28. G.G. Anderson, S.M. Martin, and S.J. Hultgren Host subversion by formation of intracellular bacterial communities in the urinary tract Microbes Infect 6 2004 1094 1101
29. H. Kumon Management of biofilm infections in the urinary tract World J Surg 10 2000 1193 1196
30. T. Goto, Y. Nakame, M. Nishida, and Y. Ohi In vitro bactericidal activities of beta-lactamases, amikacin, and fluoroquinolones against Pseudomonas aeruginosa biofilm in artificial urine Urology 53 1999 1058 1062
31. Grassi C, Salvatori E, Rosignoli MT, Dionisio P; Prulifloxacin Study Group. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 2002;69:217-22.
32. G. Reato, A.M. Cuffini, and V. Tullio Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils Int J Antimicrob Agents 23 2004 150 154
33. V. Tullio, A.M. Cuffini, and A. Bonino Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin J Antimicrob Chemother 46 2000 241 247
34. G. Aubert, A. Carricajo, and A.C. Vautrin Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit J Hosp Infect 59 2005 83 89
35. R.E. Polk, C.K. Johnson, D. McClish, R.P. Wenzel, and M.B. Edmond Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities Clin Infect Dis 39 2004 497 503
36. S.M. Bhavnani, W.A. Callen, and A. Forrest Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals Am J Health Syst Pharm 60 2003 1962 1970